Literature DB >> 10348701

Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation.

H M Jantzen1, L Gousset, V Bhaskar, D Vincent, A Tai, E E Reynolds, P B Conley.   

Abstract

The identity of the receptors mediating platelet activation by ADP remains elusive. To distinguish between platelet ADP receptor subtypes, the effects of antagonists on platelet responses and the cloned P2Y1 receptor, a putative platelet ADP receptor, have been investigated. 2-methylthio-AMP (2MeSAMP), an inhibitor of ADP-dependent platelet aggregation, antagonized ADP-mediated inhibition of adenylyl cyclase, competed with binding of [3H]2-methylthio-ADP and inhibited the stimulation of [35S]GTPgammaS binding. 2MeSAMP did not inhibit platelet shape change and was only a weak antagonist of intracellular calcium mobilization in platelets or in cells expressing the cloned human P2YI receptor. By contrast, the P2Y1 receptor antagonist adenosine 3',5'-diphosphate (A3P5P) inhibited ADP-induced platelet aggregation, completely abolished shape change, but did not antagonize ADP effects on cyclic AMP generation or [3H]2-methylthio-ADP binding. However, A3P5P antagonized intracellular calcium mobilization in platelets and cells expressing the cloned P2Y1 receptor. Furthermore, using a specific monoclonal antibody and flow cytometry, P2Y1 receptor protein was detected on human platelets. These results support the existence of two G protein-coupled ADP receptors mediating platelet aggregation, one of which is coupled to Gi proteins and blocked by 2MeSAMP, whereas the second receptor is similar or identical to P2Y1 and coupled to Gq.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348701

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  24 in total

1.  The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Authors:  Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-13       Impact factor: 3.000

2.  [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors.

Authors:  Dayle Houston; Michihiro Ohno; Robert A Nicholas; Kenneth A Jacobson; T Kendall Harden
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

3.  P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions.

Authors:  S F Maloney; Lawrence F Brass; S L Diamond
Journal:  Integr Biol (Camb)       Date:  2010-01-05       Impact factor: 2.192

4.  Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.

Authors:  A Sugidachi; F Asai; K Yoneda; R Iwamura; T Ogawa; K Otsuguro; H Koike
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 5.  P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.

Authors:  Gary A Weisman; Lucas T Woods; Laurie Erb; Cheikh I Seye
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-09       Impact factor: 4.388

6.  The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.

Authors:  A Sugidachi; F Asai; T Ogawa; T Inoue; H Koike
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.

Authors:  C J Foster; D M Prosser; J M Agans; Y Zhai; M D Smith; J E Lachowicz; F L Zhang; E Gustafson; F J Monsma; M T Wiekowski; S J Abbondanzo; D N Cook; M L Bayne; S A Lira; M S Chintala
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

8.  Potassium 2-(1-hydroxypentyl)-benzoate inhibits ADP-induced rat platelet aggregation through P2Y1-PLC signaling pathways.

Authors:  Hongyan Yang; Shaofeng Xu; Jiang Li; Ling Wang; Xiaoliang Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-03-19       Impact factor: 3.000

9.  Insulin-like growth factor-1 regulates platelet activation through PI3-Kalpha isoform.

Authors:  Soochong Kim; Analia Garcia; Shaun P Jackson; Satya P Kunapuli
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

10.  Identification of the active metabolite of ticlopidine from rat in vitro metabolites.

Authors:  Kenji Yoneda; Ryou Iwamura; Hiroko Kishi; Yoichi Mizukami; Kimiko Mogami; Sei Kobayashi
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.